Mondello Patrizia, Younes Anas
Department of Human Pathology, University of Messina, Via C. Valeria, 98100 Messina, Italy.
Expert Rev Anticancer Ther. 2015 Apr;15(4):439-51. doi: 10.1586/14737140.2015.1009042. Epub 2015 Feb 5.
Diffuse large B-cell lymphoma (DLBCL) is the most frequent non-Hodgkin lymphoma in western countries. Despite the addition of rituximab to chemotherapy, the prognosis is still poor and almost one-third of patients fail or relapse after first-line treatment. Gene expression profiling has identified three main signatures related to subgroups with different biological characteristics and responses to treatment. Novel agents targeting the oncogenic drivers of these subsets are currently under investigation with the aim of providing a tailored approach and avoiding unnecessary toxicity. Herein, we review the emerging therapies for DLBCL with a focus on preclinical and early clinical trials as well as future directions.
弥漫性大B细胞淋巴瘤（DLBCL）是西方国家最常见的非霍奇金淋巴瘤。尽管在化疗中添加了利妥昔单抗，但预后仍然很差，近三分之一的患者在一线治疗后失败或复发。基因表达谱分析已经确定了与具有不同生物学特征和治疗反应的亚组相关的三种主要特征。目前正在研究针对这些亚组致癌驱动因素的新型药物，目的是提供一种量身定制的方法并避免不必要的毒性。在此，我们综述了DLBCL的新兴疗法，重点关注临床前和早期临床试验以及未来方向。
